Buy MOTS-c: Sourcing Standards for Mitochondrial-Derived Research Peptides

Search for “buy MOTS-c” and you will find a market that has grown around a peptide that is genuinely different from most research compounds. MOTS-c is not a synthetic analog of a human hormone. It is a peptide encoded by mitochondrial DNA, a relatively recent discovery that has opened a new area of research into how mitochondria communicate with the nucleus. The compound is studied for its role in metabolic regulation, exercise response, and cellular stress resistance.

This guide is written for laboratory researchers who need to evaluate a MOTS-c supplier before placing an order. It covers what the published literature says about the compound, how the FDA’s regulatory posture toward MOTS-c has evolved, how to read a certificate of analysis without getting misled, and the specific questions that separate a transparent supplier from one that is hoping you will not ask.

What MOTS-c is, and what the research shows

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. The sequence is MRWQEMGYIFYPRKLR, with a molecular weight of approximately 2,174 Da. It was discovered in 2015 by researchers at the University of Southern California Leonard Davis School of Gerontology. The discovery paper published in Cell Metabolism described MOTS-c as a mitochondrial-derived peptide that regulates metabolic homeostasis by activating AMPK, a central regulator of cellular energy balance.

The mechanism is distinct from other research peptides. MOTS-c translocates to the nucleus in response to metabolic stress and regulates the expression of genes involved in antioxidant response and metabolic adaptation. A 2016 review by the discovery team proposed that MOTS-c targets skeletal muscle and may act as an exercise mimetic, while noting that the effect of exercise on MOTS-c production was not yet known.

A study published in 2021 in Nature Communications reported that MOTS-c treatment improved physical performance in young, middle-aged and old mice, and that exercise increased endogenous MOTS-c levels in human skeletal muscle and circulation. The treatment findings were limited to preclinical models.

What the research does not establish is a safe and effective dose for any human use. The MOTS-c literature is dominated by animal models and in-vitro studies. Human data remain limited: a Phase 1a/1b trial of CB4211, a MOTS-c analogue, has been completed, and a Phase 2a study of MOTS-c (NCT07505745) began recruiting in 2026, but no human efficacy or safety profile has been established.

The regulatory status of MOTS-c

MOTS-c is not an FDA-approved drug. It has not received authorization from the FDA, the European Medicines Agency, or any other national regulatory body for human use. The compound is sold as a research-use-only laboratory chemical, and the Stack Research MOTS-c product page states that the product is supplied only for lawful in-vitro laboratory or analytical research and that the page provides no dosing, administration, treatment, or diagnostic guidance.

The regulatory history of MOTS-c follows a pattern similar to other research peptides. In 2023, the FDA placed a group of peptides, including MOTS-c, into Category 2 of the interim 503A bulk drug substances list. Category 2 designation signals that the FDA has identified significant safety concerns, and compounders using a Category 2 substance risk FDA action while evaluation continues.

In April 2026, the FDA removed 12 peptides from Category 2, including MOTS-c, after their nominations were withdrawn, and scheduled a Pharmacy Compounding Advisory Committee discussion of MOTS-c for July 23, 2026. Legal analysis from Orrick notes that the removal does not constitute authorization for compounding but moves the substances into a regulatory grey zone pending formal review.

For researchers, the practical implication is that the regulatory environment around MOTS-c is unsettled. A supplier that claims the compound is legal to sell for human use is misrepresenting the current regulatory posture. A supplier that sells it as a research-use-only chemical and provides analytical documentation is operating within a recognized research supply channel.

The researcher’s sourcing checklist for MOTS-c

The difference between a defensible purchase and a gamble comes down to documentation. Here is what to check, in order.

1. Lot-specific certificate of analysis, not a generic sample

A certificate of analysis (COA) is only meaningful if it corresponds to the exact lot you are buying. A supplier that shows a single COA for “MOTS-c” without tying it to a lot number is showing you marketing material, not a laboratory report. The COA should list the lot number, the testing laboratory, the report ID, the date the sample was received, and the date the results were published.

Stack Research publishes a lot-specific report for its MOTS-c 10 mg research peptide. The current lot documentation shows HPLC purity, measured content, and identity confirmation by mass spectrometry. The report identifies the testing laboratory and includes a report ID that can be cross-referenced. The product page shows the exact SKU, lot number, laboratory, report ID, and sample dates alongside the price.

2. What the COA actually tests

A certificate that lists only “purity: 99%” is incomplete. The useful fields are identity, purity by HPLC, measured content, endotoxin, and sterility. Identity confirms the peptide sequence matches the reference standard. Purity by HPLC shows the percentage of the sample that is the target compound. Measured content tells you how much peptide is actually in the vial, which can differ from the label. Endotoxin and sterility results speak to the handling conditions.

If a supplier’s COA omits measured content or endotoxin, that is a gap. It may not be a dealbreaker for every research context, but it is a data point about how thoroughly the supplier tests its material.

3. The research-use-only boundary

Every legitimate research peptide supplier uses the research-use-only (RUO) designation. The RUO label means the product is not intended for diagnostic, therapeutic, or human use. It is a legal boundary, not a suggestion.

What to watch for is a supplier that uses the RUO label while simultaneously publishing dosing information, before-and-after photos, or customer testimonials about human use. That combination is what the FDA has cited in warning letters. A supplier that maintains the boundary consistently is easier to trust because it is not trying to have it both ways.

4. Pricing and configuration transparency

MOTS-c vials are typically sold in 5 mg and 10 mg configurations. The price per milligram should be calculable from the listing. If the listing obscures the vial size, bundles it with accessories, or requires a minimum order to see pricing, that is friction that makes comparison harder. Stack Research lists its 10 mg MOTS-c vial at $99.90 with volume pricing available to verified research accounts. The product page shows the exact SKU and lot information alongside the price, which makes the listing auditable.

How Stack Research approaches MOTS-c documentation

Stack Research is a research peptide supplier that publishes lot-specific documentation for each product configuration. The company’s testing page describes the analytical methods used and the laboratories that perform the work. For researchers who need to verify a supplier before ordering, the relevant questions are whether the documentation is specific to the lot, whether the testing laboratory is named, and whether the results can be independently reviewed.

The MOTS-c product page shows the current lot report directly on the page, with the purity, measured content, and identity results visible without requiring a separate download. The COA library collects the reports for all products so that researchers can compare documentation across configurations. The company maintains a research-use-only boundary throughout its product descriptions and does not publish dosing or administration guidance.

Comparing MOTS-c documentation standards

</